Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Patent
1996-04-08
1998-09-29
Hollinden, Gary E.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
424 111, 424 165, 534 14, 514 54, 53612312, A61K 5100, A61M 3614
Patent
active
058142991
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/US 94/08501 filed Jul. 28, 1994
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents, methods and kits for making the agents, and methods for using the agents to image pathological sites, including sites of infection, inflammation, cancer and atherosclerosis in a mammalian body. Specifically the agents and reagents are derivatives of oligosaccharides, more specifically .beta.-glucans.
2. Description of the Prior Art
In the field of nuclear medicine, certain pathological conditions can be localized or the extent of such conditions determined by imaging the internal distribution of administered radioactively-labeled tracer compounds (i.e. radiotracers or radiopharmaceuticals) that accumulate specifically at the pathological site. This type of procedure is commonly known as radioimaging or scintigraphic imaging. Radioimaging has particular advantages over other methods of diagnosis in that it is essentially non-invasive, highly sensitive, highly specific, can be used to scan the entire body and is relatively cost-effective. A variety of radionuclides are known to be useful for radioimaging, including .sup.67 Ga, .sup.68 Ga, .sup.99m Tc, .sup.111 In, .sup.123 I, .sup.125 I or .sup.201 Tl.
There is a clinical need to be able to determine the location and/or extent of sites of focal or localized infection. In a substantial number of cases conventional methods of diagnosis (such as physical examination, x-ray, CT and ultrasonography) fail to identify such sites (e.g., an abscess). In some cases, biopsy may be resorted to, but is preferably avoided at least until it is necessary in order to identify the pathogen responsible for an abscess at a known location. Identifying the site of such "occult" infection is important because rapid localization of the problem is critical to effective therapeutic intervention.
An abscess may be caused by any one of many possible pathogens, so that a radiotracer specific for a particular pathogen would have limited scope. On the other hand, infection is almost invariably accompanied by inflammation, which is a general response of the body to tissue injury. Therefore, a radiotracer specific for sites of inflammation would be expected to be useful in localizing sites of infection caused by any pathogen.
One of the main phenomena associated with inflammation is the localization of leukocytes (white blood cells), including macrophages, monocytes and neutrophils, at the site of inflammation. A radiotracer specific for leukocytes would be useful in detecting leukocytes at the site of a localized infection.
Currently approved nuclear medicine procedures for imaging sites of infection use either indium-111 labeled leukocytes (.sup.111 In-WBC) (see, e.g. Peters, 1992, J. Nucl. Med. 33: 65-67) or gallium-67 (.sup.67 Ga) citrate (see, e.g. Ebright et al., 1982, Arch. Int. Med. 142: 246-254).
A major disadvantage of using .sup.111 In-labeled WBCs is that the preparation of the radiotracer requires sterile removal of autologous blood, sterile isolation of the leukocytes from the blood, sterile labeling of the leukocytes using conditions that do not damage the cells (since damaged WBC are taken up by the reticuloendothelial system when re-injected) and return (re-injection) of the (now labeled) leukocytes to the patient. Furthermore, a delay of 12 to 48 hours between injection and imaging may be required for optimal images. While .sup.99m Tc labeled leukocytes have been used to shorten this delay period (see, e.g. Vorne et al., 1989, J. Nucl. Med. 30: 1332-1336), ex-corporeal labeling is still required. A preferred radiotracer would be one that does not require removal and manipulation of autologous blood components.
.sup.67 Ga- citrate can be administered by intravenous injection. However, this compound is not specific for
REFERENCES:
patent: 4385046 (1983-05-01), Milbrath et al.
patent: 4431626 (1984-02-01), Henze
patent: 5208324 (1993-05-01), Klaveness et al.
patent: 5336762 (1994-08-01), Ranney
patent: 5368840 (1994-11-01), Unger
patent: 5422095 (1995-06-01), Hasiguchi et al.
patent: 5443815 (1995-08-01), Dean et al.
patent: 5508020 (1996-04-01), Dean et al.
patent: 5561220 (1996-10-01), Dean et al.
patent: 5582172 (1996-12-01), Papisov et al.
patent: 5607677 (1997-03-01), Jamas et al.
Diatide, Inc.
Hollinden Gary E.
Jones Dameron
McDaniels Patricia A.
Noonan Kevin E.
LandOfFree
Radiolabeled glucans comprising a single thiol containing moiety does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radiolabeled glucans comprising a single thiol containing moiety, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiolabeled glucans comprising a single thiol containing moiety will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-683975